Contrary to loss-of-function NSD1 mutations in cancers, which suggest a tumor suppressor function, NSD2 has emerged as an oncogenic gene with elevated expression or hyperactive mutations in multiple human cancers, including colorectal, prostate, and lung cancers. This evidence concerns the gene NSD1 and cancer.